In a cohort encompassing 63.4% of patients with HR+/HER2− BC, Moura Leite et al. [42] found that the difference between the pCR rates of HER2-low tumors and HER2-zero tumors was not statistically significant at 13% vs. 9.5%, respectively, with no predictive value for pCR after standard NAC. Here, ERBB2 is linked to breast cancer.